Mustafa Cengiz Dura, Ismet Yagiz Dundar, Ozgur Aslan, Sukru Yildiz, Gulden Uzer Ekin, Murat Ekin
{"title":"Comparison of the Anaemia and Transfusion Rates of Pregnant Women Treated with Intravenous <em>versus</em> Oral Iron in the Third Trimester.","authors":"Mustafa Cengiz Dura, Ismet Yagiz Dundar, Ozgur Aslan, Sukru Yildiz, Gulden Uzer Ekin, Murat Ekin","doi":"10.29271/jcpsp.2024.10.1183","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate and compare the blood transfusion requirements during delivery in third-trimester pregnant women with iron deficiency anaemia (IDA) who were treated with intravenous (IV) ferric carboxymaltose (FCM) versus those treated with oral iron supplementation.</p><p><strong>Study design: </strong>Comparative study. Place and Duration of the Study: Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkiye, from January 2017 to December 2022.</p><p><strong>Methodology: </strong>Pregnant women with haemoglobin (Hb) levels <10 g/dL in their third trimester were included. One group (n = 50) received IV FCM, while the other group (n = 96) received oral iron therapy. Key outcome measures included Hb levels at delivery and the need for a postpartum blood transfusion. Inclusion criteria were third-trimester pregnancy with IDA, and exclusion criteria included haematological or chronic systemic diseases and high-risk pregnancies.</p><p><strong>Results: </strong>The mean initial Hb levels in the third trimester of pregnancy in the FCM group and oral iron group were 8.31 ± 0.96 g/dL and 9.29 ± 1.20 g/dL, respectively (p <0.001). The mean Hb levels in the delivery room were 11.09 ± 1.38 and 9.44 ± 1.16 g/dL, respectively (p <0.001). The rates of postpartum erythrocyte transfusion requirement were 6% (n = 3) and 18.75% (n = 18), respectively (p = 0.037).</p><p><strong>Conclusion: </strong>IV FCM administration to pregnant patients with IDA during the third trimester was found to be more effective than oral iron treatment in reducing blood transfusion rates.</p><p><strong>Key words: </strong>Anaemia, Ferric carboxymaltose, Pregnancy, Iron deficiency, Intravenous iron.</p>","PeriodicalId":94116,"journal":{"name":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29271/jcpsp.2024.10.1183","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate and compare the blood transfusion requirements during delivery in third-trimester pregnant women with iron deficiency anaemia (IDA) who were treated with intravenous (IV) ferric carboxymaltose (FCM) versus those treated with oral iron supplementation.
Study design: Comparative study. Place and Duration of the Study: Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkiye, from January 2017 to December 2022.
Methodology: Pregnant women with haemoglobin (Hb) levels <10 g/dL in their third trimester were included. One group (n = 50) received IV FCM, while the other group (n = 96) received oral iron therapy. Key outcome measures included Hb levels at delivery and the need for a postpartum blood transfusion. Inclusion criteria were third-trimester pregnancy with IDA, and exclusion criteria included haematological or chronic systemic diseases and high-risk pregnancies.
Results: The mean initial Hb levels in the third trimester of pregnancy in the FCM group and oral iron group were 8.31 ± 0.96 g/dL and 9.29 ± 1.20 g/dL, respectively (p <0.001). The mean Hb levels in the delivery room were 11.09 ± 1.38 and 9.44 ± 1.16 g/dL, respectively (p <0.001). The rates of postpartum erythrocyte transfusion requirement were 6% (n = 3) and 18.75% (n = 18), respectively (p = 0.037).
Conclusion: IV FCM administration to pregnant patients with IDA during the third trimester was found to be more effective than oral iron treatment in reducing blood transfusion rates.
Key words: Anaemia, Ferric carboxymaltose, Pregnancy, Iron deficiency, Intravenous iron.
目的评估并比较患有缺铁性贫血(IDA)的第三孕期孕妇在分娩时接受静脉注射羧甲基铁(FCM)治疗与口服铁补充剂治疗的输血需求:比较研究。研究地点和时间土耳其伊斯坦布尔 Bakirkoy Dr. Sadi Konuk 培训与研究医院,2017 年 1 月至 2022 年 12 月:孕妇血红蛋白(Hb)水平结果:在降低输血率方面,对妊娠三个月内患有 IDA 的孕妇进行静脉注射羧酸铁比口服铁剂治疗更有效:贫血;羧甲基铁;妊娠;缺铁;静脉注射铁剂。